Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin

Circulation Research

Volumn 84, Issue 6, 1999, Pages 729-734

  Ding, Bo ^a   Price, Robert L ^b   Borg, Thomas K ^b   Weinberg, Ellen O ^a   Halloran, Philip F ^d   Lorell, Beverly H ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NONE

Author keywords

Atrial natriuretic factor; Calcineurin; Cyclosporine; Heart hypertrophy; Mice

Indexed keywords

CALCINEURIN; CYCLOSPORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

EID: 0033515619     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.6.729     Document Type: Article

References (32)

1. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 1991;5:3037-3046.
2. Morgan HE, Baker K. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-25.
3. Schneider MD, Parker TG. Cardiac myocytes as targets for the action of peptide growth factors. Circulation. 1990;81:1443-1456.
4. Homcy CJ. Signaling hypertrophy: how many switches, how many wires? Circulation. 1998;97:1890-1892.
5. Batuik TD, Halloran PF. The downstream consequences of calcineurin inhibition. Transplant Proc. 1997;29:1239-1240.
6. Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
7. Baringa M. Signaling path may lead to better heart-failure therapies. Science. 1998;280:383.
8. Izumo S, Aoki H. Calcineurin: the missing link in cardiac hypertrophy. Nat Med. 1998;4:661-662.
9. 1 receptor inhibition: effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation. 1997;95:1592-1600.
10. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 1993;73:184-192.
11. Weinberg EO, Schoen FJ, George D, Kagaya, U, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90:1410-1422.
12. Schunkert H, Weinberg EO, Bruckschlegel G, Reigger AJG, Lorell BH. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. J Clin Invest. 1995;96: 2768-2774.
13. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation. 1999;99:127-134.
14. Fruman DA, Klee CB, Brierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine. Proc Natl Acad Sci USA. 1992;89:3686-3690.
15. 50 for in vivo cyclosporine in mouse. Transplantation. 1996;61:1618-1624.
16. Batiuk TD, Pazderka F, Enns J, De Castro L, Halloran PF. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation. 1996;61:158-161.
17. Batuik TD, Hung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest. 1997; 100:1894-1901.
18. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. Cis-acting sequences that mediate induction of the α-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation. 1997;96:3943-3953.
19. Molkentin JD, Olson E. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation. 1997;96:3833-3835.
20. Shaw KTY, Ho AM, Raghavan A, Kim J, Jian J, Park J, Sharma S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA. 1995;92:11205-11209.
21. Sussman MA, Lim HW, Gude N, Taigen T, Olson ER, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281: 1690-1693.
22. Luo Z, Shyu K-G, Gualberto A, Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med 1998;4:1092-1093. Letter.
23. Müller JG, Nemoto S, Laser M, Carabello BA, Menick DR. Calcineurin inhibition and cardiac hypertrophy [technical comment]. Science. 1998; 282:1007a. Available at: http://www.sciencemag.org/cgi/content/full/ 282/5391/1007a.
24. Zou Y, Kornuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Yazaki Y. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin Il-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271:33592-33597.
25. Bowman JC, Steinberg SF, Jiang T, Geenan DL, Fishman GI, Buttrick PM. Expression of protein kinase C β in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 1997;100: 2189-2195.
26. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, Wight DC, Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GSα overexpression. Circ Res. 1996;78:517-234.
27. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
28. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K, Yazaki Y. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998;97:1952-1959.
29. Kudoh S, Komuro I, Yukio H, Zou Y, Harada K, Sugaya T, Takekoshi N, Murakami K, Kadowaki T, Yazaki Y. Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. J Biol Chem. 1998;273:24037-24043.
30. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
31. Rowan RA, Billingham ME. Pathologic changes in the long-term transplanted heart: a morphometric study of myocardial hypertrophy, vascularity, and fibrosis. Hum Pathol. 1990;21:767-772.
32. Imakita M, Tazelaar HD, Rowan RA, Masek MA, Billingham ME. Myocyte hypertrophy in the transplanted heart. A morphometric analysis. Transplantation. 1987;43:839-842.